Beaumont Financial Advisors LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Beaumont Financial Advisors LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,182 shares of the medical research company’s stock after buying an additional 33 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. Bornite Capital Management LP increased its holdings in shares of Thermo Fisher Scientific by 50.0% during the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after acquiring an additional 10,000 shares in the last quarter. Fairfield Bush & CO. raised its holdings in Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock worth $1,729,000 after buying an additional 36 shares during the last quarter. Loomis Sayles & Co. L P raised its holdings in Thermo Fisher Scientific by 563.5% in the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock worth $11,721,000 after buying an additional 16,853 shares during the last quarter. Covestor Ltd raised its holdings in Thermo Fisher Scientific by 60.5% in the first quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock worth $190,000 after buying an additional 121 shares during the last quarter. Finally, Merit Financial Group LLC raised its holdings in Thermo Fisher Scientific by 3.6% in the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

TMO opened at $544.79 on Friday. The firm has a market cap of $207.95 billion, a P/E ratio of 35.26, a PEG ratio of 2.28 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a 50 day simple moving average of $571.27 and a two-hundred day simple moving average of $527.45. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period in the prior year, the business posted $5.40 earnings per share. The company’s revenue was down 4.9% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. HSBC boosted their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday. Finally, The Goldman Sachs Group boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.